This is in line with an earlier study reporting lack of wild-type p53 accumulation on BA treatment as well as association between p53 mutation status and BA sensitivity in another paediatric cancer, namely neuroblastoma (Fulda et al, 1997). The gene discussed is TP53; the disease is cancer.